2BBBullish & Bearish
Inovio Pharmaceuticals, Inc. (INO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 32 out of 100.
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.
Inovio Pharmaceuticals, Inc.’s current 2BB score is 32 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 38 | Low |
| Momentum | 70 | Improving |
| Financial strength | 0 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 54 | Moderate |
| CEO | Jacqueline Shea |
| Founded | 1999 |
| Employees | 112 |
| 52-week range | $0.57 – $2.98 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-09 | — | -0.2054 | — | $0.00 |
| 2026-08-12 | — | -0.2188 | — | $0.00 |
| 2026-05-13 | -0.28 | -0.3535 | $0.00 | $252,500.00 |
| 2026-03-12 | 0.06 | -0.3614 | $0.00 | $0.00 |